Literature DB >> 35108028

Revisiting UGT1A1 Pharmacogenetic Testing Before Irinotecan-Why Not?

Lukas P Emery1, Gabriel A Brooks1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35108028      PMCID： PMC9014453          DOI： 10.1200/OP.21.00840

Source DB:  PubMed          Journal:  JCO Oncol Pract        ISSN： 2688-1527


× No keyword cloud information.
  8 in total

1.  FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.

Authors:  Thierry Conroy; Pascal Hammel; Mohamed Hebbar; Meher Ben Abdelghani; Alice C Wei; Jean-Luc Raoul; Laurence Choné; Eric Francois; Pascal Artru; James J Biagi; Thierry Lecomte; Eric Assenat; Roger Faroux; Marc Ychou; Julien Volet; Alain Sauvanet; Gilles Breysacher; Frédéric Di Fiore; Christine Cripps; Petr Kavan; Patrick Texereau; Karine Bouhier-Leporrier; Faiza Khemissa-Akouz; Jean-Louis Legoux; Béata Juzyna; Sophie Gourgou; Christopher J O'Callaghan; Claire Jouffroy-Zeller; Patrick Rat; David Malka; Florence Castan; Jean-Baptiste Bachet
Journal:  N Engl J Med       Date:  2018-12-20       Impact factor: 91.245

2.  Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.

Authors:  Federico Innocenti; Richard L Schilsky; Jacqueline Ramírez; Linda Janisch; Samir Undevia; Larry K House; Soma Das; Kehua Wu; Michelle Turcich; Robert Marsh; Theodore Karrison; Michael L Maitland; Ravi Salgia; Mark J Ratain
Journal:  J Clin Oncol       Date:  2014-06-23       Impact factor: 44.544

3.  UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity: A meta-analysis.

Authors:  Yuwei Yang; MengMeng Zhou; Mingjun Hu; Yanjie Cui; Qi Zhong; Ling Liang; Fen Huang
Journal:  Asia Pac J Clin Oncol       Date:  2018-06-22       Impact factor: 2.601

4.  Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study.

Authors:  D J Crona; J Ramirez; W Qiao; A-J de Graan; M J Ratain; R H N van Schaik; R H J Mathijssen; G L Rosner; F Innocenti
Journal:  Pharmacogenomics J       Date:  2015-04-14       Impact factor: 3.550

5.  UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients.

Authors:  Emma C Hulshof; Mirjam de With; Femke M de Man; Geert-Jan Creemers; Birgit A L M Deiman; Jesse J Swen; Saskia Houterman; Stijn L W Koolen; Sander Bins; Anna M J Thijs; Marjan M J Laven; Anke M Hövels; Saskia A C Luelmo; Danny Houtsma; Katerina Shulman; Howard L McLeod; Ron H N van Schaik; Henk-Jan Guchelaar; Ron H J Mathijssen; Hans Gelderblom; Maarten J Deenen
Journal:  Eur J Cancer       Date:  2022-01-05       Impact factor: 9.162

6.  All You Need to Know About UGT1A1 Genetic Testing for Patients Treated With Irinotecan: A Practitioner-Friendly Guide.

Authors:  Spinel Karas; Federico Innocenti
Journal:  JCO Oncol Pract       Date:  2021-12-03

7.  Expanding evidence leads to new pharmacogenomics payer coverage.

Authors:  Philip E Empey; Victoria M Pratt; James M Hoffman; Kelly E Caudle; Teri E Klein
Journal:  Genet Med       Date:  2021-02-24       Impact factor: 8.822

8.  Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians.

Authors:  X Liu; D Cheng; Q Kuang; G Liu; W Xu
Journal:  Pharmacogenomics J       Date:  2013-03-26       Impact factor: 3.550
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.